CLOSE

Breast Cancer Medical Treatments

highlight

The Division is aimed to provide comprehensive care of all the types and phases (preoperative, adjuvant, advanced disease) of breast cancer with active clinical and translational research, integrating  outpatient and in-patient areas through a common support.

Our Activities

The Division of Medical Senology provides care and conducts research in an integrated fashion in the field of breast cancer.

The principle of providing the best personalized care for the individual patient with breast cancer, with full respect for quality of life and proper communication, is the best support for competitive and innovative clinical research. The principle shared by members of the Division is that increased participation in clinical trials would increase learning about the disease and improve patient care. Weekly multidisciplinary meetings for both the preoperative, adjuvant and advanced setting are planned in order to properly address a tailored clinical and investigational approach.

  • Our staff
     

    Breast Cancer Medical Treatments

    Director

    Marco Angelo Colleoni

    Staff Breast Cancer Medical Treatments

  • Clinical Trials
    • IBCSG 42-12/BIG 2-12 SNAP. “A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer”. EudraCT Number: 2012-003058-10
    • IBCSG 41-13 TREND. “A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for primary endocrine responsive breast cancer”. EudraCT number: 2012-005326-29
    • IEO S582/111. A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients: VEX STUDY. EudraCT 2010-024266-21.
    • IEO S479/209. Phase II study with Epirubicin, Cisplatin and infusional Fluorouracil (ECF) followed by weekly Paclitaxel plus metronomic Cyclophosphamide ± Trastuzumab and endocrine therapy as preoperative treatment of locally advanced breast cancer EudraCT N.: 2009-012048-18
    • IEO S733/612. WAVE: Weekly nab-paclitaxel (Abraxane®) Versus Epirubicin in women with early breast cancer who are elderly or unfit for a 3-weekly polychemotherapy regimen: a Phase II Randomized Trial evaluating Activity and Quality of Life”, EudraCT N. 2012-004489-17

     

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

facebook IEO googleplus IEO twitter IEO pinterest IEO vimeo IEO